LIFEVANTAGE CORP Revenue
LIFEVANTAGE CORP (LFVN) reported Revenue of $182.59 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-27
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $42.38M, a 23.11% decline year-over-year.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $43.72M, a 25.20% decline year-over-year.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $48.93M, a 27.79% decline year-over-year.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $47.56M, a 0.73% increase year-over-year.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for fiscal 2026 was $182.59M, a 20.10% decline from fiscal 2025.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for fiscal 2025 was $228.53M, a 14.17% increase from fiscal 2024.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for fiscal 2024 was $200.16M, a 6.20% decline from fiscal 2023.
- LIFEVANTAGE CORP revenue from contract with customer, excluding assessed tax for fiscal 2023 was $213.40M, a 3.41% increase from fiscal 2022.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $86.09M derived: sum of 2 quarters · filed 2026-08-27 | $135.02M derived: sum of 3 quarters · filed 2026-08-27 | $182.59M 10-K · filed 2026-08-27 |
| 2026-03-31 | $43.72M 10-Q · filed 2026-05-06 | $92.65M derived: sum of 2 quarters · filed 2026-05-06 | $140.21M 10-Q · filed 2026-05-06 | $195.32M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | $48.93M 10-Q · filed 2026-02-04 | $96.49M 10-Q · filed 2026-02-04 | $151.61M derived: sum of 3 quarters · filed 2026-08-27 | $210.05M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | $47.56M 10-Q · filed 2025-11-04 | $102.67M derived: sum of 2 quarters · filed 2026-08-27 | $161.12M derived: sum of 3 quarters · filed 2026-08-27 | $228.88M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | $55.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $113.55M derived: sum of 2 quarters · filed 2026-08-27 | $181.32M derived: sum of 3 quarters · filed 2026-08-27 | $228.53M 10-K · filed 2026-08-27 |
| 2025-03-31 | $58.44M 10-Q · filed 2026-05-06 | $126.20M derived: sum of 2 quarters · filed 2026-05-06 | $173.42M 10-Q · filed 2026-05-06 | $222.35M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $67.76M 10-Q · filed 2026-02-04 | $114.98M 10-Q · filed 2026-02-04 | $163.91M derived: sum of 3 quarters · filed 2026-02-04 | $212.15M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-09-30 | $47.21M 10-Q · filed 2025-11-04 | $96.14M derived: sum of 2 quarters · filed 2025-11-04 | $144.39M derived: sum of 3 quarters · filed 2025-11-04 | $196.01M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $48.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | $97.18M derived: sum of 2 quarters · filed 2025-09-04 | $148.80M derived: sum of 3 quarters · filed 2025-09-04 | $200.16M 10-K · filed 2025-09-04 |
| 2024-03-31 | $48.24M 10-Q · filed 2025-05-06 | $99.87M derived: sum of 2 quarters · filed 2025-05-06 | $151.23M 10-Q · filed 2025-05-06 | $205.45M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $51.62M 10-Q · filed 2025-02-05 | $102.99M 10-Q · filed 2025-02-05 | $157.21M derived: sum of 3 quarters · filed 2025-02-05 | $210.95M derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-09-30 | $51.36M 10-Q · filed 2024-10-29 | $105.58M derived: sum of 2 quarters · filed 2024-10-29 | $159.33M derived: sum of 3 quarters · filed 2024-10-29 | $212.99M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $54.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-28 | $107.96M derived: sum of 2 quarters · filed 2024-08-28 | $161.62M derived: sum of 3 quarters · filed 2024-08-28 | $213.40M 10-K · filed 2024-08-28 |
| 2023-03-31 | $53.74M 10-Q · filed 2024-05-02 | $107.40M derived: sum of 2 quarters · filed 2024-05-02 | $159.18M 10-Q · filed 2024-05-02 | $210.12M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $53.66M 10-Q · filed 2024-01-30 | $105.44M 10-Q · filed 2024-01-30 | $156.38M derived: sum of 3 quarters · filed 2024-01-30 | $206.38M derived: sum of 4 quarters · filed 2024-01-30 |
| 2022-09-30 | $51.77M 10-Q · filed 2023-11-09 | $102.72M derived: sum of 2 quarters · filed 2023-11-09 | $152.72M derived: sum of 3 quarters · filed 2023-11-09 | $204.91M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $50.94M 10-K · filed 2022-08-23 | $100.95M derived: sum of 2 quarters · filed 2023-05-04 | $153.14M derived: sum of 3 quarters · filed 2023-05-04 | $206.36M 10-K · filed 2023-08-28 |
| 2022-03-31 | $50.00M 10-Q · filed 2023-05-04 | $102.19M derived: sum of 2 quarters · filed 2023-05-04 | $155.42M 10-Q · filed 2023-05-04 | $210.19M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $52.19M 10-Q · filed 2023-02-02 | $105.41M 10-Q · filed 2023-02-02 | $160.19M derived: sum of 3 quarters · filed 2023-02-02 | $211.76M derived: sum of 4 quarters · filed 2023-02-02 |
| 2021-09-30 | $53.22M 10-Q · filed 2022-11-02 | $108.00M derived: sum of 2 quarters · filed 2022-11-02 | $159.57M derived: sum of 3 quarters · filed 2022-11-02 | $218.58M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $54.78M 10-K · filed 2022-08-23 | $106.35M derived: sum of 2 quarters · filed 2022-08-23 | $165.35M derived: sum of 3 quarters · filed 2022-08-23 | $220.18M 10-K · filed 2022-08-23 |
| 2021-03-31 | $51.57M 10-K · filed 2022-08-23 | $110.58M derived: sum of 2 quarters · filed 2022-08-23 | $165.41M 10-Q · filed 2022-05-03 | $224.77M derived: sum of 4 quarters · filed 2022-08-23 |
| 2020-12-31 | $59.01M 10-K · filed 2022-08-23 | $113.83M 10-Q · filed 2022-02-01 | $173.20M derived: sum of 3 quarters · filed 2022-08-23 | $229.28M derived: sum of 4 quarters · filed 2022-08-23 |
| 2020-09-30 | $54.83M 10-K · filed 2022-08-23 | $114.19M derived: sum of 2 quarters · filed 2022-08-23 | $170.27M derived: sum of 3 quarters · filed 2022-08-23 | $231.51M derived: sum of 4 quarters · filed 2022-08-23 |
| 2020-06-30 | $59.37M 10-K · filed 2021-08-19 | $115.44M derived: sum of 2 quarters · filed 2021-08-19 | $176.69M derived: sum of 3 quarters · filed 2021-08-19 | $232.91M 10-K · filed 2022-08-23 |
| 2020-03-31 | $56.08M 10-K · filed 2021-08-19 | $117.32M derived: sum of 2 quarters · filed 2021-08-19 | $173.55M 10-Q · filed 2021-04-29 | $229.72M derived: sum of 4 quarters · filed 2021-08-19 |
| 2019-12-31 | $61.24M 10-K · filed 2021-08-19 | $117.47M 10-Q · filed 2021-02-02 | $173.64M derived: sum of 3 quarters · filed 2021-08-19 | $229.65M derived: sum of 4 quarters · filed 2021-08-19 |
| 2019-09-30 | $56.23M 10-K · filed 2021-08-19 | $112.40M derived: sum of 2 quarters · filed 2021-08-19 | $168.41M derived: sum of 3 quarters · filed 2021-08-19 | $226.58M derived: sum of 4 quarters · filed 2021-08-19 |
| 2019-06-30 | $56.17M 10-K · filed 2020-08-18 | $112.18M derived: sum of 2 quarters · filed 2020-08-18 | $170.35M derived: sum of 3 quarters · filed 2020-08-18 | $225.96M 10-K · filed 2021-08-19 |
| 2019-03-31 | $56.01M 10-K · filed 2020-08-18 | $114.18M derived: sum of 2 quarters · filed 2020-08-18 | $169.79M 10-Q · filed 2020-05-05 | $223.82M derived: sum of 4 quarters · filed 2020-08-18 |
| 2018-12-31 | $58.17M 10-K · filed 2020-08-18 | $113.78M 10-Q · filed 2020-01-28 | $167.81M derived: sum of 3 quarters · filed 2020-08-18 | $218.37M derived: sum of 4 quarters · filed 2020-08-18 |
| 2018-09-30 | $55.61M 10-K · filed 2020-08-18 | $109.64M derived: sum of 2 quarters · filed 2020-08-18 | $160.20M derived: sum of 3 quarters · filed 2020-08-18 | $209.69M derived: sum of 4 quarters · filed 2020-08-18 |
| 2018-06-30 | $54.03M 10-K · filed 2019-08-14 | $104.59M derived: sum of 2 quarters · filed 2019-08-14 | $154.08M derived: sum of 3 quarters · filed 2019-08-14 | $203.20M 10-K · filed 2020-08-18 |
| 2018-03-31 | $50.56M 10-K · filed 2019-08-14 | $100.04M derived: sum of 2 quarters · filed 2019-08-14 | $149.17M 10-Q · filed 2019-05-01 | |
| 2017-12-31 | $49.48M 10-K · filed 2019-08-14 | $98.61M 10-Q · filed 2019-02-04 | ||
| 2017-09-30 | $49.13M 10-K · filed 2019-08-14 | |||
| 2017-06-30 | $199.49M 10-K · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |